vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Rumble Inc. (RUM). Click either name above to swap in a different company.
Rumble Inc. is the larger business by last-quarter revenue ($27.1M vs $16.1M, roughly 1.7× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -120.8%, a 113.0% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -10.5%). Over the past eight quarters, Rumble Inc.'s revenue compounded faster (15.2% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Rumble is a Canadian-American online video platform, web hosting, and cloud services business headquartered in Toronto, Canada, with its U.S. headquarters in Longboat Key, Florida. It was founded in 2013 by Chris Pavlovski, a Canadian technology entrepreneur. Rumble's cloud services business hosts Truth Social, and the video platform is popular among American conservative and far-right users. Rumble has been described as "alt-tech".
DERM vs RUM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $27.1M |
| Net Profit | $-1.2M | $-32.7M |
| Gross Margin | — | 5.5% |
| Operating Margin | -2.8% | -131.1% |
| Net Margin | -7.8% | -120.8% |
| Revenue YoY | 27.3% | -10.5% |
| Net Profit YoY | -182.0% | 86.2% |
| EPS (diluted) | $-0.04 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $27.1M | ||
| Q3 25 | $17.0M | $24.8M | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $13.1M | $23.7M | ||
| Q4 24 | $12.6M | $30.2M | ||
| Q3 24 | $14.6M | $25.1M | ||
| Q2 24 | $14.9M | $22.5M | ||
| Q1 24 | $13.0M | $17.7M |
| Q4 25 | $-1.2M | $-32.7M | ||
| Q3 25 | $-2.3M | $-16.3M | ||
| Q2 25 | $-3.8M | — | ||
| Q1 25 | $-4.1M | $-2.7M | ||
| Q4 24 | $1.5M | $-236.8M | ||
| Q3 24 | $-2.4M | $-31.5M | ||
| Q2 24 | $-3.4M | $-26.8M | ||
| Q1 24 | $-10.4M | $-43.3M |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | 82.3% | -14.2% | ||
| Q3 24 | 63.9% | -45.4% | ||
| Q2 24 | 56.0% | -58.8% | ||
| Q1 24 | 47.7% | -79.5% |
| Q4 25 | -2.8% | -131.1% | ||
| Q3 25 | -9.0% | -113.6% | ||
| Q2 25 | -19.2% | — | ||
| Q1 25 | -25.3% | -153.5% | ||
| Q4 24 | 17.7% | -80.1% | ||
| Q3 24 | -19.8% | -131.0% | ||
| Q2 24 | -19.7% | -172.7% | ||
| Q1 24 | -77.4% | -197.4% |
| Q4 25 | -7.8% | -120.8% | ||
| Q3 25 | -13.6% | -65.7% | ||
| Q2 25 | -25.3% | — | ||
| Q1 25 | -31.0% | -11.2% | ||
| Q4 24 | 12.1% | -783.2% | ||
| Q3 24 | -16.3% | -125.9% | ||
| Q2 24 | -22.6% | -119.2% | ||
| Q1 24 | -80.1% | -244.1% |
| Q4 25 | $-0.04 | $-0.13 | ||
| Q3 25 | $-0.09 | $-0.06 | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.18 | $-0.01 | ||
| Q4 24 | $0.10 | $-1.17 | ||
| Q3 24 | $-0.12 | $-0.15 | ||
| Q2 24 | $-0.17 | $-0.13 | ||
| Q1 24 | $-0.53 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $237.9M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $274.8M |
| Total Assets | $94.6M | $336.8M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $237.9M | ||
| Q3 25 | $24.9M | $269.8M | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | $301.3M | ||
| Q4 24 | $20.3M | $114.0M | ||
| Q3 24 | $22.5M | $132.0M | ||
| Q2 24 | $23.9M | $154.2M | ||
| Q1 24 | $24.1M | $183.8M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $274.8M | ||
| Q3 25 | $25.9M | $302.2M | ||
| Q2 25 | $19.2M | — | ||
| Q1 25 | $21.5M | $339.6M | ||
| Q4 24 | $20.1M | $-63.1M | ||
| Q3 24 | $10.9M | $166.1M | ||
| Q2 24 | $11.3M | $192.7M | ||
| Q1 24 | $13.0M | $210.7M |
| Q4 25 | $94.6M | $336.8M | ||
| Q3 25 | $85.2M | $367.2M | ||
| Q2 25 | $81.2M | — | ||
| Q1 25 | $85.0M | $391.1M | ||
| Q4 24 | $80.2M | $195.3M | ||
| Q3 24 | $64.0M | $217.2M | ||
| Q2 24 | $65.2M | $243.2M | ||
| Q1 24 | $66.6M | $263.0M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-31.7M |
| FCF MarginFCF / Revenue | — | -117.2% |
| Capex IntensityCapex / Revenue | — | 8.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-70.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-29.4M | ||
| Q3 25 | $-2.4M | $-10.6M | ||
| Q2 25 | $-942.0K | — | ||
| Q1 25 | $-2.8M | $-14.5M | ||
| Q4 24 | $2.2M | $-12.4M | ||
| Q3 24 | $-1.2M | $-19.1M | ||
| Q2 24 | $-5.2M | $-21.7M | ||
| Q1 24 | $-5.0M | $-33.9M |
| Q4 25 | — | $-31.7M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-14.6M | ||
| Q4 24 | — | $-12.4M | ||
| Q3 24 | — | $-19.9M | ||
| Q2 24 | — | $-23.1M | ||
| Q1 24 | — | $-34.3M |
| Q4 25 | — | -117.2% | ||
| Q3 25 | — | -48.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -61.7% | ||
| Q4 24 | — | -40.9% | ||
| Q3 24 | — | -79.5% | ||
| Q2 24 | — | -102.8% | ||
| Q1 24 | — | -193.3% |
| Q4 25 | — | 8.5% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 6.1% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
